紫茜合剂对CITP患者临床疗效及对FasL的影响
|
摘要
目的：观察紫茜合剂对慢性免疫性血小板减少症(Chronic immune thrombocytopenia,CITP)用药前后的总症状积分、PLT计数及外周血死亡因子配体Fask的变化,以探讨对CITP的疗效、CITP的病变机理及紫茜合剂对本病的作用环节,为该药进一步应用于临床提供理论依据
方法：30例CITP患者给予紫茜合剂口服,用药两疗程(每疗程两个月)之后,通过与用药前CITP患者的总症状积分、PLT、FasL做对比分析,进行中西医疗效判定
结果:l、紫茜合剂对CITP患者的总有效率为86.67%。对疗前疗后患者临床总症状积分和血小板计数结果做统计学分析,结果显示有统计学意义(P<0.01)。2、CITP患者外周血FasL水平较疗前及正常对照组明显升高,经治疗后有所下降,疗前、疗后结果做配对t检验有统计学意义(P<0.01)。
结论
1、紫茜合剂对CITP患者有效,总有效率为86.67%。2、经治疗后CITP患者的血小板有所回升；外周血FasL水平有所下降。3、CITP患者FasL高表达可能影响了细胞免疫环节,介导T淋巴细胞的异常凋亡,导致CITP的发生。4、紫茜合剂可能通过降低CITP患者的FasL水平,促使T淋巴细胞正常凋亡,维持机体免疫平衡而达到治疗CITP的目的
Objective:To observe the effects of ZI QIAN compound on the treatment of chronic immune thrombocytopenia (CITP) through the changes of the total symptom score,PLT count and peripheral blood death factor ligand Fasl. To discuss the mechanism of CITP and the effect of ZI QIAN compound to CITP and provide the theoretical basis for the further clinical application of ZI QIAN compound.
Methods:30 patients with CITP were treated with the ZI QIAN compound for two courses which contain two months, Evaluate the effects of ZI QIAN compound through the comparative analysis of changes of the total symptom score-, PLT count and peripheral blood death factor ligand Fasl.
Results:
1.the total effective rate of ZI QIAN compound to the CITP patients is 86.67%. Statistical analysis of the total symptom score and the clinical results of PLT count showed that the results was statistically significant (P<0.01).
2.Compared with the patients with CITP before the treatment of ZI QIAN compound and control groups.the level of Fasl of the patients after the treatment was decreased significantly (P<0.01).
Conclusions:
1.ZI QIAN compound can decrease the total symptom score of the patients with CITP.
2.The PLT count of the patients with CITP after the treatment was increased but the level of the Fasl was decreased.
3.The high expression of Fasl of the patients with CITP may affect the cellular immune links and medicate the abnormal apoptosis of T lymphocytes and lead to CITP.
4.ZI QIAN compound may maintain the normal T lymphocyte apoptosis to play a role in the treatment of CITP through decreasing the level of Fasl of the patients with CITP.
方法：30例CITP患者给予紫茜合剂口服,用药两疗程(每疗程两个月)之后,通过与用药前CITP患者的总症状积分、PLT、FasL做对比分析,进行中西医疗效判定
结果:l、紫茜合剂对CITP患者的总有效率为86.67%。对疗前疗后患者临床总症状积分和血小板计数结果做统计学分析,结果显示有统计学意义(P<0.01)。2、CITP患者外周血FasL水平较疗前及正常对照组明显升高,经治疗后有所下降,疗前、疗后结果做配对t检验有统计学意义(P<0.01)。
结论
1、紫茜合剂对CITP患者有效,总有效率为86.67%。2、经治疗后CITP患者的血小板有所回升；外周血FasL水平有所下降。3、CITP患者FasL高表达可能影响了细胞免疫环节,介导T淋巴细胞的异常凋亡,导致CITP的发生。4、紫茜合剂可能通过降低CITP患者的FasL水平,促使T淋巴细胞正常凋亡,维持机体免疫平衡而达到治疗CITP的目的
Objective:To observe the effects of ZI QIAN compound on the treatment of chronic immune thrombocytopenia (CITP) through the changes of the total symptom score,PLT count and peripheral blood death factor ligand Fasl. To discuss the mechanism of CITP and the effect of ZI QIAN compound to CITP and provide the theoretical basis for the further clinical application of ZI QIAN compound.
Methods:30 patients with CITP were treated with the ZI QIAN compound for two courses which contain two months, Evaluate the effects of ZI QIAN compound through the comparative analysis of changes of the total symptom score-, PLT count and peripheral blood death factor ligand Fasl.
Results:
1.the total effective rate of ZI QIAN compound to the CITP patients is 86.67%. Statistical analysis of the total symptom score and the clinical results of PLT count showed that the results was statistically significant (P<0.01).
2.Compared with the patients with CITP before the treatment of ZI QIAN compound and control groups.the level of Fasl of the patients after the treatment was decreased significantly (P<0.01).
Conclusions:
1.ZI QIAN compound can decrease the total symptom score of the patients with CITP.
2.The PLT count of the patients with CITP after the treatment was increased but the level of the Fasl was decreased.
3.The high expression of Fasl of the patients with CITP may affect the cellular immune links and medicate the abnormal apoptosis of T lymphocytes and lead to CITP.
4.ZI QIAN compound may maintain the normal T lymphocyte apoptosis to play a role in the treatment of CITP through decreasing the level of Fasl of the patients with CITP.
引文
[1]侯明.成人特发性血小板减少性紫癜诊断治疗专家共识[J].中华血液学杂志,2009,30(9):574-575.
[2]周全良, 陈学达.陈学达运用柴平生血汤治疗特发性血小板减少性紫癜经验[J].中医药临床杂志,2006,18(3):219-220.
[3]甘欣锦,张文曦.原发性血小板减少性紫癜辨治思路[J].辽宁中医杂志,2006,33(1)： 29.
[4]尹艳.孙伟正教授治疗顽固性原发性血小板减少性紫癜经验[J].中医药信息,2005,22(2):55-56.
[5]乔晓丽, 赵玉成.中医治疗特发性血小板减少性紫癜[J].中国中医药,2005,3(3)：29.
[6]甘欣锦, 张文曦.特发性血小板减少性紫癜辨治思路[J].辽宁中医杂志,2006,33(1)：29.
[7]陈永辉.特发性血小板减少性紫癜分期论治[J]. 中医药研究2001,2(17)：29.
[8]李新成.止癜汤治疗慢性特发性血小板减少性紫癜临床观察[J].湖北中医杂志,2007,29(7):29.
[9]陈碾等.自拟新加归脾合剂治疗特发性血小板减少性紫癜临床研究[J].北京中医,2006,25(4):221-222.
[10]刘敏,宋明福, 赵为军,王安桥. “生血二号”治疗慢性特发性血小板减少性紫癜36例临床研究[J].四川中医,2008,26(11):2.
[11]周清华,魏自敏.消斑饮口服液治疗慢性特发性血小板减少性紫癜100例[J].实用中医内科杂志,2004,12(2):141.
[12]赵天升, 肖荣芬自拟止血消斑汤施治血小板减少性紫癜[J].时珍国医国药,2005,16(4): 340.
[13]王伟智,范国田.凉血益气汤治疗特发性血小板减少性紫癜24例 [J].医学创新研究,2008,5(20):107.
[14]潘迎英.益气升板汤系益气升板汤治疗特发性血.小板减少性紫癜 65例[J].中华临床医学杂志,2005,18(22):1606.
[15]宋振邦等.自拟羊枣黄茂汤加味治疗特发性血.小板减少性紫癜36例[J].辽宁中医杂志,2006,33(3):316-317.
[16]沈伟, 徐旻, 姚乃中.补肾方治疗难治性血小板减少性紫癜 40例的临床疗效观察[J].黑龙江中医药,2007,6(4): 5-6.
[17]陈一清.血小板减少性紫癜辨证施治规律若干问题探要[J].中医药学刊,2005,23(8):1457-1459.
[18]徐瑞荣.中西医结合治疗难治性特发性血小板减少性紫癜疗效观察[J].中国中医急诊,2004,13(1):19-20.
[19]孙晓伟,孙伟止,邹长鹏等.中西医结合治疗原发性血小板减少性紫癜80例临床观察[J].中医药学报,2005,33(6):41-42.
[20]李国荣.补益清宁汤治疗小儿特发性血小板减少性紫癜 45例[J].实用中医内科杂志,2004,18(2)： 142.
[21]王明松. 中西医结合治疗慢性血小板减少性紫癜的效果观察[J].中医中药,2010,7(26):69.
[22]马玉德,万桔梅.中两医结合治疗特发性血小板减少性紫癜51例疗效观察[J].云南中医中药杂志,2008,29(4)：15.
[23]周爱萍,单丽娟.中西医结合治疗慢性特发性血小板减少性紫癜疗效观察[J].新疆中医药,2007,25(3)：52-53.
[24]张媛媛, 许华, 陈治珍,张广丽, 吴仙娜, 陈伙莲. 中药配合激素治疗小儿慢性血小板减少性紫癜29例[J].广西中医,2010,3 1(3):303.
[25]单丽娟, 秦兰, 杜晓军. 中西医结合治疗老年难治原发性血小板减少性紫癜临床观察[J]. 中华中医药杂志,2010,25(8):1337-1339.
[26]张惠荣,宁建英,杨红.特发性血小板减少性紫癜T淋巴细胞亚群和免疫球蛋白变化[J].实用儿科临床杂志,2004,19(5):361-362.
[27]崔明辰,鄢文海,干建国,等.HPV-B19感染与儿童特发性血小板减少性紫癜的关系[J].山东医药,2008,5(1)：40.
[28]束晓梅, 冒青.人细小病毒B19感染与儿童急性特发性血.小板减少性紫癜发病关系的探讨 [J].中医实用儿科杂志,2003,18(4):230-231.
[29]严媚,古丽娜.人类微小病毒B19与小儿血液病的关系[J].新疆医科大学学报,2003,26:5.
[30]张宝荣,干欣,解丽娟,等.小儿特发性血小板减少性紫癜病毒感染的分析[J].中国小儿血.液与肿瘤杂志,2006,71(01):1386-1394.
[31]刘玉.急性甲型病毒性肝炎伴血小板减少1例[J].临床军医杂志2003,14(06)： 908-916.
[32]Kooter AJ, derlinden PW,De Klerk C,et al. Acute idiopathic thromboeytoPenie PurPura in adults following viral infection report of two cases[J]. NethJMed,2002,60(4):174.
[33]王玉双,孙树勋.人类巨细胞病毒感染与儿童特发性血小板减少性紫癜[J].华北煤炭医学院学报,2002,4(2)：145-146.
[34]A ndoK,Shmi amotoT,Tauchi T,etal.Can eradication therapy forhe-liobacter pylori really mi prove t he thrombocytopenia in idiopathic thrombocytopenic pupura? [J]. Int. Hemato,l 2003,77(3):239-244.
[35]SHIGETO N,SHIMIZU S.Eradi cation of Heliobacter pylori for idiopathic thrombocytopenic purpura[J]. Nippon Shokakibyo Gakai Zasshi,2004,101(6):598-60.
[36]武四云,李艳明,简子娟,唐发清ITP患者抗幽门螺杆菌治疗的疗效观察 中南大学学报(医学版)2009,34(12)1251-1254.
[37]方敏,鲍仁孝,赵丽萍,等.慢性特发性血小板减少性紫癜与幽门螺杆菌感染的关系[J].实用儿科临床杂志,2007,22(03):211-224.
[38]赵瑾,季峰.幽门螺杆菌与特发性血小板减少性紫癜发病关系的研究进展[J].国际消化病杂志,2008,28(1)：20-22.
[39]周静,廖娟,蒋能刚,等.原发性血小板减少性紫癜患者血小板抗体的表达及其对血.小板数量和功能的影响[J].四川大学学报(医学版),2007,23(6)：246-250.
[40]周璞,侯明.原发性血小板减少性紫癜的细胞免疫机制[J].中华血液学杂志,2003,24(9):502-503.
[41]ZhouB,ZhouH,YangRC,etal.Muiti-dysfunction pathophysiogy in TP[J]. Critrevoncol Hematol,2005,54 (2):107.
[42]盛光耀,王春美. 特发性血小板减少性紫癜发病机制研究进展[J].实用儿科临床杂志,2010,25(3)：157-159.
[43]周静,龙丹,丁彬,等.自身反应性T淋巴细胞在抗血小板抗体产生中的作用[J].四川大学学报：医学版,2007,38(4)： 653-656.
[44]伏瑞祥 吴德沛.CD4+CD25+T细胞在ITP发病中的作用[J].现代免疫学杂志,2004,24:32.
[45]Wilson BS,Delovitch TL.Janus-like role of regulatory NKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol,2003,3, 211-222.
[46]张国栋,闵捷.细胞免疫及体液免疫在ITP发生发展中的作用及其机制探讨[J].山东医药,2007,47(17)：35-36.
[47]Olsson B, Andersson PO, Jernas M,et al.T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J].Natl Med,2003,9(9):1123-1124.
[48]J ohanssonU,Macey MG, Kenny D,et al. The role of natural killer T (NKT) cells in immune thrombocytopenia:Is strong in vitro NKT cell activity related to the development of remission[J]?Br J Haematol,2005, 129(4):564-565.
[49]Wu CL,Xu JC,XiH,et al. Polarization and apoptosis of T cell subsets in idiopathic thrombocytopenic purpura[J].Int J Lab Hematol,2007,29 (3) 177-184.
[50]杨小猛,刘仿,陈群.特发性血小板减少性紫癜病因学研究进展[J]中国小儿血液,2004,9(3):139-142.
[51]韩智娟.特发性血小板减少性紫癜242例临床分析[J].新医学,2003,35(6)： 325-335.
[52]Fox SW, Chambers TJ. The effect of oestrogen on megakaryocyte differentiation and platelet counts in vivo [J]. Int J Cardio,l 2006,109(3): 359-366.
[53]Terrell DR, Johnson KK,Vesely SK,et al Is immune thrombocytopenic purpura less common among black Americans? [J]. Blood,2005,105(3): 1368-1369.
[54]陈银霞,秦岚,张王刚等.霉酚酸酷对难治性ITP患者疗效及免疫功 能影响[J].第四军医大学学报,2004,25(8):715-717.
[55]洪少杰,唐小玲.霉酚酸酷治疗难治性特发性血小板减少性紫癜 16例疗效观察[J]中国实用内科杂志,2005,25(6):531-532.
[56]侯明.糖皮质激素耐药特发性血小板减少性紫癜治疗进展[J].中国实用内科杂志,2008,28(10):817-819.
[57]赵永强,王庆余,翟明,等.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8)：608-610.
[58]Kuter DJ, Bussel JB, Lyons RM,et al Efficacy of romiplostmi in patients with chronic immune thrombocytopenic purpura:a double-blind randomized controlled trial [J].Lancet 2008,371(9610):395-403-
[59]Bussel JB, Kuter DJ, deWolf JT,et al Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update [J].Blood (ASH AnnualMeetingAbstracts),2007,110(11): 568.
[60]陆再英,钟南山.内科学(第七版)[M].北京：人民卫生出版社,2009,650.
[61]周仲瑛.中医内科学(新世纪第二版)[M].中国中医药出版社,2007,393-394.
[62]宋锦叶,孟立强等.黄芪与当归的现代药理与研究进展[J].中国中西医结合肾病杂志,2008,9:834.
[63]李黎星,康李芳.中药党参的研究进展[J].现代生物医学进展2009,12：2372.
[64]黄冬度.旱莲草治疗再生障碍性贫血[J].中医杂志,2004,45(1)：11.
[65]卢晓沅,陈志良,下春霞.女贞子化学成分及其药理作用研究概况[J].中药材 2006,29(6): 627-628.
[66]陈静.大剂量生地为主治疗原发性血小板减少性紫癜 10例[J].贵阳中医学报2003,25(2):18-19.
[67]李晓瑾,药用植物紫草的研究进展[J].新疆师范大学学报,2005, 24(4)：70.
[68]方晓艳, 孙艳红, 杨林莎.茜草的研究进展[J].河南中医药学刊2002,17 (5)： 78-79.
[69]陈东辉,罗霞,余梦瑶等.鸡血藤煎剂对小鼠骨髓细胞增殖的影响[J].中国中药杂志,2004,29(4)352-355.
[70]孟玮.白花蛇舌草对小鼠骨髓细胞增殖和1L-2生成的影响[J].滨洲医学院学报,2004,27(4)：257.
[71]郑永利.甘草及甘草制剂的临床应用研究进展[J].内蒙古中医药,2009,(9)74-75.
[72]李志英.特发性血小板减少性紫癜细胞免疫功能及细胞因子的变化[J].实用儿科临床杂志,2004,19(9):805-806.
[73]Bidinger B, Torres R, Rossetti RG,et al.Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes[J].Clin Immunol,2003,108 (2):95-102.
[2]周全良, 陈学达.陈学达运用柴平生血汤治疗特发性血小板减少性紫癜经验[J].中医药临床杂志,2006,18(3):219-220.
[3]甘欣锦,张文曦.原发性血小板减少性紫癜辨治思路[J].辽宁中医杂志,2006,33(1)： 29.
[4]尹艳.孙伟正教授治疗顽固性原发性血小板减少性紫癜经验[J].中医药信息,2005,22(2):55-56.
[5]乔晓丽, 赵玉成.中医治疗特发性血小板减少性紫癜[J].中国中医药,2005,3(3)：29.
[6]甘欣锦, 张文曦.特发性血小板减少性紫癜辨治思路[J].辽宁中医杂志,2006,33(1)：29.
[7]陈永辉.特发性血小板减少性紫癜分期论治[J]. 中医药研究2001,2(17)：29.
[8]李新成.止癜汤治疗慢性特发性血小板减少性紫癜临床观察[J].湖北中医杂志,2007,29(7):29.
[9]陈碾等.自拟新加归脾合剂治疗特发性血小板减少性紫癜临床研究[J].北京中医,2006,25(4):221-222.
[10]刘敏,宋明福, 赵为军,王安桥. “生血二号”治疗慢性特发性血小板减少性紫癜36例临床研究[J].四川中医,2008,26(11):2.
[11]周清华,魏自敏.消斑饮口服液治疗慢性特发性血小板减少性紫癜100例[J].实用中医内科杂志,2004,12(2):141.
[12]赵天升, 肖荣芬自拟止血消斑汤施治血小板减少性紫癜[J].时珍国医国药,2005,16(4): 340.
[13]王伟智,范国田.凉血益气汤治疗特发性血小板减少性紫癜24例 [J].医学创新研究,2008,5(20):107.
[14]潘迎英.益气升板汤系益气升板汤治疗特发性血.小板减少性紫癜 65例[J].中华临床医学杂志,2005,18(22):1606.
[15]宋振邦等.自拟羊枣黄茂汤加味治疗特发性血.小板减少性紫癜36例[J].辽宁中医杂志,2006,33(3):316-317.
[16]沈伟, 徐旻, 姚乃中.补肾方治疗难治性血小板减少性紫癜 40例的临床疗效观察[J].黑龙江中医药,2007,6(4): 5-6.
[17]陈一清.血小板减少性紫癜辨证施治规律若干问题探要[J].中医药学刊,2005,23(8):1457-1459.
[18]徐瑞荣.中西医结合治疗难治性特发性血小板减少性紫癜疗效观察[J].中国中医急诊,2004,13(1):19-20.
[19]孙晓伟,孙伟止,邹长鹏等.中西医结合治疗原发性血小板减少性紫癜80例临床观察[J].中医药学报,2005,33(6):41-42.
[20]李国荣.补益清宁汤治疗小儿特发性血小板减少性紫癜 45例[J].实用中医内科杂志,2004,18(2)： 142.
[21]王明松. 中西医结合治疗慢性血小板减少性紫癜的效果观察[J].中医中药,2010,7(26):69.
[22]马玉德,万桔梅.中两医结合治疗特发性血小板减少性紫癜51例疗效观察[J].云南中医中药杂志,2008,29(4)：15.
[23]周爱萍,单丽娟.中西医结合治疗慢性特发性血小板减少性紫癜疗效观察[J].新疆中医药,2007,25(3)：52-53.
[24]张媛媛, 许华, 陈治珍,张广丽, 吴仙娜, 陈伙莲. 中药配合激素治疗小儿慢性血小板减少性紫癜29例[J].广西中医,2010,3 1(3):303.
[25]单丽娟, 秦兰, 杜晓军. 中西医结合治疗老年难治原发性血小板减少性紫癜临床观察[J]. 中华中医药杂志,2010,25(8):1337-1339.
[26]张惠荣,宁建英,杨红.特发性血小板减少性紫癜T淋巴细胞亚群和免疫球蛋白变化[J].实用儿科临床杂志,2004,19(5):361-362.
[27]崔明辰,鄢文海,干建国,等.HPV-B19感染与儿童特发性血小板减少性紫癜的关系[J].山东医药,2008,5(1)：40.
[28]束晓梅, 冒青.人细小病毒B19感染与儿童急性特发性血.小板减少性紫癜发病关系的探讨 [J].中医实用儿科杂志,2003,18(4):230-231.
[29]严媚,古丽娜.人类微小病毒B19与小儿血液病的关系[J].新疆医科大学学报,2003,26:5.
[30]张宝荣,干欣,解丽娟,等.小儿特发性血小板减少性紫癜病毒感染的分析[J].中国小儿血.液与肿瘤杂志,2006,71(01):1386-1394.
[31]刘玉.急性甲型病毒性肝炎伴血小板减少1例[J].临床军医杂志2003,14(06)： 908-916.
[32]Kooter AJ, derlinden PW,De Klerk C,et al. Acute idiopathic thromboeytoPenie PurPura in adults following viral infection report of two cases[J]. NethJMed,2002,60(4):174.
[33]王玉双,孙树勋.人类巨细胞病毒感染与儿童特发性血小板减少性紫癜[J].华北煤炭医学院学报,2002,4(2)：145-146.
[34]A ndoK,Shmi amotoT,Tauchi T,etal.Can eradication therapy forhe-liobacter pylori really mi prove t he thrombocytopenia in idiopathic thrombocytopenic pupura? [J]. Int. Hemato,l 2003,77(3):239-244.
[35]SHIGETO N,SHIMIZU S.Eradi cation of Heliobacter pylori for idiopathic thrombocytopenic purpura[J]. Nippon Shokakibyo Gakai Zasshi,2004,101(6):598-60.
[36]武四云,李艳明,简子娟,唐发清ITP患者抗幽门螺杆菌治疗的疗效观察 中南大学学报(医学版)2009,34(12)1251-1254.
[37]方敏,鲍仁孝,赵丽萍,等.慢性特发性血小板减少性紫癜与幽门螺杆菌感染的关系[J].实用儿科临床杂志,2007,22(03):211-224.
[38]赵瑾,季峰.幽门螺杆菌与特发性血小板减少性紫癜发病关系的研究进展[J].国际消化病杂志,2008,28(1)：20-22.
[39]周静,廖娟,蒋能刚,等.原发性血小板减少性紫癜患者血小板抗体的表达及其对血.小板数量和功能的影响[J].四川大学学报(医学版),2007,23(6)：246-250.
[40]周璞,侯明.原发性血小板减少性紫癜的细胞免疫机制[J].中华血液学杂志,2003,24(9):502-503.
[41]ZhouB,ZhouH,YangRC,etal.Muiti-dysfunction pathophysiogy in TP[J]. Critrevoncol Hematol,2005,54 (2):107.
[42]盛光耀,王春美. 特发性血小板减少性紫癜发病机制研究进展[J].实用儿科临床杂志,2010,25(3)：157-159.
[43]周静,龙丹,丁彬,等.自身反应性T淋巴细胞在抗血小板抗体产生中的作用[J].四川大学学报：医学版,2007,38(4)： 653-656.
[44]伏瑞祥 吴德沛.CD4+CD25+T细胞在ITP发病中的作用[J].现代免疫学杂志,2004,24:32.
[45]Wilson BS,Delovitch TL.Janus-like role of regulatory NKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol,2003,3, 211-222.
[46]张国栋,闵捷.细胞免疫及体液免疫在ITP发生发展中的作用及其机制探讨[J].山东医药,2007,47(17)：35-36.
[47]Olsson B, Andersson PO, Jernas M,et al.T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J].Natl Med,2003,9(9):1123-1124.
[48]J ohanssonU,Macey MG, Kenny D,et al. The role of natural killer T (NKT) cells in immune thrombocytopenia:Is strong in vitro NKT cell activity related to the development of remission[J]?Br J Haematol,2005, 129(4):564-565.
[49]Wu CL,Xu JC,XiH,et al. Polarization and apoptosis of T cell subsets in idiopathic thrombocytopenic purpura[J].Int J Lab Hematol,2007,29 (3) 177-184.
[50]杨小猛,刘仿,陈群.特发性血小板减少性紫癜病因学研究进展[J]中国小儿血液,2004,9(3):139-142.
[51]韩智娟.特发性血小板减少性紫癜242例临床分析[J].新医学,2003,35(6)： 325-335.
[52]Fox SW, Chambers TJ. The effect of oestrogen on megakaryocyte differentiation and platelet counts in vivo [J]. Int J Cardio,l 2006,109(3): 359-366.
[53]Terrell DR, Johnson KK,Vesely SK,et al Is immune thrombocytopenic purpura less common among black Americans? [J]. Blood,2005,105(3): 1368-1369.
[54]陈银霞,秦岚,张王刚等.霉酚酸酷对难治性ITP患者疗效及免疫功 能影响[J].第四军医大学学报,2004,25(8):715-717.
[55]洪少杰,唐小玲.霉酚酸酷治疗难治性特发性血小板减少性紫癜 16例疗效观察[J]中国实用内科杂志,2005,25(6):531-532.
[56]侯明.糖皮质激素耐药特发性血小板减少性紫癜治疗进展[J].中国实用内科杂志,2008,28(10):817-819.
[57]赵永强,王庆余,翟明,等.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8)：608-610.
[58]Kuter DJ, Bussel JB, Lyons RM,et al Efficacy of romiplostmi in patients with chronic immune thrombocytopenic purpura:a double-blind randomized controlled trial [J].Lancet 2008,371(9610):395-403-
[59]Bussel JB, Kuter DJ, deWolf JT,et al Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update [J].Blood (ASH AnnualMeetingAbstracts),2007,110(11): 568.
[60]陆再英,钟南山.内科学(第七版)[M].北京：人民卫生出版社,2009,650.
[61]周仲瑛.中医内科学(新世纪第二版)[M].中国中医药出版社,2007,393-394.
[62]宋锦叶,孟立强等.黄芪与当归的现代药理与研究进展[J].中国中西医结合肾病杂志,2008,9:834.
[63]李黎星,康李芳.中药党参的研究进展[J].现代生物医学进展2009,12：2372.
[64]黄冬度.旱莲草治疗再生障碍性贫血[J].中医杂志,2004,45(1)：11.
[65]卢晓沅,陈志良,下春霞.女贞子化学成分及其药理作用研究概况[J].中药材 2006,29(6): 627-628.
[66]陈静.大剂量生地为主治疗原发性血小板减少性紫癜 10例[J].贵阳中医学报2003,25(2):18-19.
[67]李晓瑾,药用植物紫草的研究进展[J].新疆师范大学学报,2005, 24(4)：70.
[68]方晓艳, 孙艳红, 杨林莎.茜草的研究进展[J].河南中医药学刊2002,17 (5)： 78-79.
[69]陈东辉,罗霞,余梦瑶等.鸡血藤煎剂对小鼠骨髓细胞增殖的影响[J].中国中药杂志,2004,29(4)352-355.
[70]孟玮.白花蛇舌草对小鼠骨髓细胞增殖和1L-2生成的影响[J].滨洲医学院学报,2004,27(4)：257.
[71]郑永利.甘草及甘草制剂的临床应用研究进展[J].内蒙古中医药,2009,(9)74-75.
[72]李志英.特发性血小板减少性紫癜细胞免疫功能及细胞因子的变化[J].实用儿科临床杂志,2004,19(9):805-806.
[73]Bidinger B, Torres R, Rossetti RG,et al.Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes[J].Clin Immunol,2003,108 (2):95-102.